Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

Transplantation

Volumn 65, Issue 12, 1998, Pages 1615-1621

  Nery, Jose R ^a   Weppler, Deborah ^a   Rodriguez, Miguel ^b   Ruiz, Phillip ^a   Schiff, Eugene R ^a   Tzakis, Andreas G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Surgery ^*

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADULT; ALLOGRAFT; ARTICLE; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; RECURRENT VIRUS INFECTION; VIREMIA; VIRUS REPLICATION;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEALTH CARE COSTS; HEPATITIS B; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE;

EID: 0032572291     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199806270-00013     Document Type: Article

References (43)

1. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619.
3. Demetris AJ, Todo S, Van Thiel D, et al. Evolution of hepatitis B virus liver disease after hepatic replacement: practical and theoretical considerations. Am J Pathol 1990; 137: 667.
4. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
5. Konig V, Hopf U, Neuhaus P, et al. Long-term follow up of hepatitis B virus- infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553.
6. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Pruett TL. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358.
7. Chossegros P, Pouteil-Noble C, Samuel D, et al. Ganciclovir is an effective antiviral agent for post-transplantation chronic HBV infections, maintenance therapy may be required in some cases. Gastroenterology 1993; 104: A888
8. Yoshida EM, Wolber RA, Mahmood WA, Anderson FH, Scudamore CH, Erb SR. Attempted resolution of acute recurrent hepatitis B in a transplanted liver allograft by the administration of ganciclovir. Transplantation 1994; 58: 956.
9. Gish RG, Lau JY, Brooks L, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 1.
10. Jamal H, Regenstein F, Farr G, Perrillo RP. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy. Am J Gastroenterol 1996; 91: 1027.
11. Angus P, Richards M, Bowden S, et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol 1993; 8: 353.
12. Singh N, Gayowski T. Lack of sustained efficacy of combination ganciclovir and foscarnet for hepatitis B virus recurrence after liver transplantation. Transplantation 1995; 59: 1629.
13. Starzl TE, Fung J, Tzakis A, et al. Baboon- to-human liver transplantation. Lancet 1993; 341: 65.
14. Flowers M, Sherker A, Sinclair SB, et al. Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation 1994; 58: 183.
15. Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19: 6.
16. Terrault NA, Holland CC, Ferrell L, et al. Interferon alpha for recurrent hepatitis B infection after liver transplantation. Liver Transplant Surg 1996; 2: 132.
17. Gish RG, Keefe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol 1995; 22: 257.
18. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099.
19. Kruger M, Tillman HL, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation: a pilot study. Hepatology 1995; 22 Pt 2: 219A.
20. Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IK. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63: 1415.
21. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495.
22. Ashman C, Larkin D, Cammak N, Boehme RE, Cameron JM. Lamivudine inhibits hepatitis B virus (HBV) production in the HBV transfected cell line 2.2.15. Paper presented at the Sixth International Symposium on Viral Hepatitis. Madrid, February 1994: 65.
23. Tyrrel DLJ, Fischer K, Savani K, Tan W, Jewell L. Treatment of chimpanzees and ducks with lamivudine, 2′,3′-dideoxy-3′-thiacytidine, results in a rapid suppression of hepaviral DNA in sera. Clin Invest Med 1993; 16 (suppl 4): B77.
24. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. Double-blind, randomized, three-month, dose-ranging trial of lamivudine for chronic hepatitis B. Hepatology 1994; 20: A412.
25. Benhamou Y, Dohin E, Lunel-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396.
26. Dienstag JL, Perrillo RP, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657.
27. Schnittman SM. Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type 1. Clin Infect Dis 1996; 23: 638.
28. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 705.
29. Lai C-L, Ching C-K, Tung AK-M, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25: 241.
30. Grellier L, Brown D, McPhillips P, Burroughs A, Rolles K, Dusheiko G. Lamivudine prophylaxis: a new strategy for prevention of reinfection in liver transplantation for hepatitis B DNA positive cirrhosis. Hepatology 1995; 22 Pt 2: 224A.
31. Gutfreund KS, Fischer KP, Tipples G, et al. Lamivudine results in a complete and sustained suppression of hepatitis B virus replication in patients requiring orthotopic liver transplantation for cirrhosis secondary to hepatitis B. Hepatology 1995; 22 Pt 2: 328A.
32. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212.
33. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 1456.
34. Ben-Ari Z, Shmuelli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997; 63: 393.
35. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20.
36. Lau D, Mostowski H, Hoofnagle JH, Sallie R. Nucleoside analogue toxicity and mitochondria. Hepatology 1994; 20: 189A.
37. Lowell JA, Burgess S, Shenoy S, Peters M, Howard TK. Mercury poisoning associated with hepatitis B immunoglobulin. Lancet 1996; 347: 480.
38. Schalm SW. Clinical implications of lamivudine resistance by HBV. Lancet 1997; 349: 3.
39. Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine ((-)-beta-L-2′,3′-dideoxy-3′-thiacytidine) in vitro. Antimicrob Agents Chemother 1996; 40: 1957.
40. Ling R, Mutimer D, Ahmed M, Boxall EH, Dusheiko GM, Harrison T. Selection of mutations in the hepatitis B virus polymerase during therapy with lamivudine. Hepatology 1996; 24: 711.
41. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrel DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714.
42. Boucher CAB, Cammack N, Schipper P, et al. High-level resistance to (-)enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231.
43. Tisdale M, Kemp SD, Parry NR, Larder BS. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90: 5653.